TSB and CR Pharma partner for Covid-19 antibody therapy in China
Pharmaceutical Technology
JULY 20, 2022
TSB Therapeutics, a joint venture (JV) majority-owned by Brii Biosciences (Brii Bio), has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy, amubarvimab/romlusevimab combination, for Covid-19 in China. .
Let's personalize your content